We've listed the best LED light panels for any size or budget, for smartphones, hotshoe mounting and studio photography When you purchase through links on our site, we may earn an affiliate commission ...

Everything is on track and the two new Salik gates scheduled to be operational by end of November are positioned to better improve the flow of traffic and reduce congestion across key roads in the ...

Screenshots of Windows Control Panel showed the upcoming Recall feature as something that could be removed. A Microsoft employee says that's a glitch.

Bill Gates, one of the wealthiest people in the world with a net worth of over $130 billion, always manages to be in the news. However, it's not because Microsoft is leading his portfolio; ...

Opinion We may not know exactly when or how, but we do know that the Windows Control Panel is gasping its last. Hurrah. A living fossil in the platform's user interface, it is many things, none of ...

Their open letter was addressed to “the Gates Foundation and other funders of industrial agriculture.” It charged these funders with promoting a type of corporate, industrial agriculture that ...

The Bill & Melinda Gates Foundation Trust had 54% of its portfolio allocated to Microsoft (33%) and Berkshire Hathaway (21%) as of the June quarter. Microsoft is the largest software company and ...

Street Talk understands GIP’s local dealmakers, led by former Credit Suisse Australia boss Rob Stewart, submitted a non-binding indicative offer for QAL but have notified the sellers of its ...

See the moment Israeli jets fly over Beirut while CNN reporter is on air ...

In response, a spokesperson for Bill Gates pushed back on the new biography "Billionaire, Nerd, Savior, King," calling it "sensationalized" Maria Pasquini is the staff editor for human interest ...

OKE is acquiring GIP’s managing member interest in ENLC for $300 million in cash and is acquiring the common units owned by GIP for $14.90 per unit, which represents a 12.8% premium to ENLC’s ...

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations.